Citadel Advisors
ADCT icon

Citadel Advisors’s ADC Therapeutics ADCT Stock Holding History

Citadel Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
399,721
+101,503
+34% +$400K ﹤0.01% 6709
2025
Q4 		$1.05M Sell
298,218
-522,497
-64% -$2.12M ﹤0.01% 7280
2025
Q3 		$3.28M Buy
820,715
+791,709
+2,729% +$2.5M ﹤0.01% 5143
2025
Q2 		$77.7K Buy
+29,006
New +$61K ﹤0.01% 11516
2024
Q3 		– Sell
-41,433
Closed -$131K – 14131
2024
Q2 		$131K Sell
41,433
-911,031
-96% -$3.62M ﹤0.01% 10543
2024
Q1 		$4.28M Sell
952,464
-900,948
-49% -$3.32M ﹤0.01% 4186
2023
Q4 		$3.08M Sell
1,853,412
-1,044,709
-36% -$964K ﹤0.01% 4604
2023
Q3 		$2.6M Sell
2,898,121
-271,728
-9% -$361K ﹤0.01% 4747
2023
Q2 		$6.82M Sell
3,169,849
-196,855
-6% -$443K ﹤0.01% 3195
2023
Q1 		$6.57M Buy
3,366,704
+1,378,836
+69% +$5.09M ﹤0.01% 3374
2022
Q4 		$7.63M Buy
1,987,868
+1,948,077
+4,896% +$7.79M ﹤0.01% 3193
2022
Q3 		$192K Buy
+39,791
New +$288K ﹤0.01% 10440
2021
Q4 		– Sell
-19,346
Closed -$467K – 13703
2021
Q3 		$525K Sell
19,346
-4,653
-19% -$119K ﹤0.01% 9741
2021
Q2 		$584K Buy
23,999
+8,837
+58% +$205K ﹤0.01% 9698
2021
Q1 		$370K Sell
15,162
-69,736
-82% -$2.02M ﹤0.01% 10362
2020
Q4 		$2.72M Buy
+84,898
New +$2.78M ﹤0.01% 4741
2020
Q3 		– Sell
-29,738
Closed -$1.39M – 9999
2020
Q2 		$1.39M Buy
+29,738
New +$1.13M ﹤0.01% 5213

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ADCT Position: Q1 2026 in Review

Citadel Advisors increased its ADC Therapeutics (ADCT) stake by 34% in Q1 2026, buying an estimated $400K and bringing the position to 399,721 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6709.

Citadel Advisors first reported a position in ADCT in Q2 2020 and has held it in 17 quarters since. The position peaked at $7.63M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Citadel Advisors held 399,721 shares of ADC Therapeutics worth $1.5M as of Q1 2026.
  • Citadel Advisors bought 101,503 ADC Therapeutics shares in Q1 2026, an estimated $400K.
  • ADC Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6709 holding.
  • Citadel Advisors first reported a position in ADC Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Citadel Advisors's ADC Therapeutics position peaked at $7.63M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.